Cencora, Inc. $COR Stock: CenterBook Partners LP Raises Position

CenterBook Partners LP raised its holdings in Cencora, Inc. (NYSE:COR) by 152.4% during the 3rd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 13,757 shares of the company’s stock after acquiring an additional 8,306 shares during the period. CenterBook Partners LP’s holdings in Cencora were worth $4,131,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in the stock. Elevation Wealth Partners LLC increased its stake in Cencora by 506.2% in the second quarter. Elevation Wealth Partners LLC now owns 97 shares of the company’s stock valued at $27,000 after acquiring an additional 81 shares during the last quarter. Bell Investment Advisors Inc purchased a new position in shares of Cencora during the 2nd quarter valued at about $28,000. Caitlin John LLC bought a new stake in shares of Cencora in the 2nd quarter worth approximately $28,000. Cassaday & Co Wealth Management LLC purchased a new stake in Cencora during the first quarter valued at about $35,000. Finally, Lynch Investment Planning LLC purchased a new stake in Cencora during the 3rd quarter valued at about $39,000. 97.52% of the stock is currently owned by hedge funds and other institutional investors.

Cencora Price Performance

Shares of COR stock opened at $333.38 on Friday. The business’s fifty day moving average is $325.07 and its 200 day moving average is $317.28. The company has a quick ratio of 0.58, a current ratio of 0.94 and a debt-to-equity ratio of 3.01. The stock has a market cap of $63.62 billion, a price-to-earnings ratio of 18.60, a PEG ratio of 1.73 and a beta of 0.58. Cencora, Inc. has a twelve month low of $244.82 and a twelve month high of $377.54.

Cencora (NYSE:COR) last announced its quarterly earnings data on Wednesday, November 4th. The company reported $4.66 EPS for the quarter, beating the consensus estimate of $4.58 by $0.08. The business had revenue of $88.35 billion during the quarter, compared to analyst estimates of $87.95 billion. Cencora had a return on equity of 110.72% and a net margin of 1.03%. The company’s revenue for the quarter was up 5.5% on a year-over-year basis. During the same quarter last year, the firm posted $3.84 earnings per share. Research analysts expect that Cencora, Inc. will post 19.58 EPS for the current fiscal year.

Cencora Increases Dividend

The firm also recently announced a quarterly dividend, which will be paid on Monday, November 30th. Shareholders of record on Friday, November 13th will be paid a dividend of $0.66 per share. This is a positive change from Cencora’s previous quarterly dividend of $0.60. This represents a $2.64 dividend on an annualized basis and a dividend yield of 0.8%. The ex-dividend date of this dividend is Friday, November 13th. Cencora’s payout ratio is 13.39%.

Insiders Place Their Bets

In other news, EVP Elizabeth Campbell sold 11,300 shares of Cencora stock in a transaction dated Monday, August 24th. The stock was sold at an average price of $324.12, for a total value of $3,662,556.00. Following the completion of the transaction, the executive vice president owned 19,455 shares of the company’s stock, valued at $6,305,754.60. The trade was a 36.74% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. 0.38% of the stock is currently owned by company insiders.

Analysts Set New Price Targets

Several analysts have weighed in on the company. Wells Fargo & Company boosted their price objective on Cencora from $331.00 to $395.00 and gave the company an “overweight” rating in a research report on Tuesday, August 11th. UBS Group cut their target price on shares of Cencora from $430.00 to $400.00 and set a “buy” rating on the stock in a report on Friday, October 16th. Robert W. Baird lifted their target price on shares of Cencora from $373.00 to $375.00 and gave the stock an “outperform” rating in a research note on Thursday, October 22nd. Wall Street Zen raised shares of Cencora from a “hold” rating to a “buy” rating in a research note on Saturday, August 8th. Finally, JPMorgan Chase & Co. upped their price target on shares of Cencora from $382.00 to $390.00 and gave the company an “overweight” rating in a report on Friday, August 7th. Thirteen research analysts have rated the stock with a Buy rating and four have given a Hold rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $368.73.

Cencora News Roundup

Here are the key news stories impacting Cencora this week:

• Positive Sentiment: Cencora beat quarterly expectations, reporting EPS of $4.66 versus estimates of $4.58 and revenue of $88.35 billion versus $87.95 billion; revenue grew 5.5% year over year. The company also issued a stronger fiscal 2027 earnings outlook, reinforcing expectations for continued growth. Cencora stock enters fiscal 2027 with stronger earnings outlook
• Positive Sentiment: Leerink Partners raised its price target to $405 from $388 and maintained an “outperform” rating, signaling confidence in potential upside.
• Positive Sentiment: Cencora raised its dividend, adding to its appeal for income-focused investors amid market uncertainty. Stocks that hiked dividends
• Neutral Sentiment: The company is realigning its corporate structure. The available report headline does not specify the changes or their expected financial impact. Cencora realigning corporate structure
• Negative Sentiment: Despite Cencora’s earnings beat, shares came under pressure after rival Cardinal Health reported results, prompting concern about relative performance and contributing to a short-term pullback. Cencora drops while rival Cardinal Health posts a beat

About Cencora

Cencora, formerly known as AmerisourceBergen, is a global pharmaceutical services company that connects pharmaceutical manufacturers with healthcare providers. Its core business includes sourcing and distributing medicines and other healthcare products to pharmacies, hospitals, health systems and other care providers.

The company also provides services supporting specialty pharmaceuticals, including logistics, consulting and solutions for manufacturers and healthcare organizations. These services help manage the handling and delivery of complex medicines and support access to treatments.

Cencora serves customers in the United States and internationally.